# SAMSRITA LABS (NSE: SAMSRITA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SAMSRITA · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹28 Cr, it ranks 3413th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.

Its return on equity was −69.4% in FY26. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹347 Cr (+8.7% year on year) and net profit ₹22 Cr (+7.0%), on a consolidated basis. Promoters held 25.44% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹28 Cr |
| ROE | −69.4% (FY26) |
| ROCE | −73.3% (FY26) |
| Debt to equity | 0.14 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹347 Cr | +8.7% | ₹22 Cr | +7.0% | ₹18.00 |
| Q4 FY26 | ₹209 Cr | +3.1% | ₹11 Cr | +55.7% | ₹8.96 |
| Q3 FY26 | ₹247 Cr | +15.3% | ₹14 Cr | +127.5% | ₹11.26 |
| Q2 FY26 | ₹255 Cr | +5.4% | ₹19 Cr | +49.9% | ₹15.12 |
| Q1 FY26 | ₹320 Cr | +31.9% | ₹21 Cr | +53.5% | ₹16.83 |
| Q4 FY25 | ₹202 Cr | — | ₹7 Cr | — | ₹5.75 |
| Q3 FY25 | ₹214 Cr | −0.1% | ₹6 Cr | −45.8% | ₹4.95 |
| Q2 FY25 | ₹242 Cr | −0.0% | ₹12 Cr | −31.7% | ₹10.09 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹0 Cr | −₹0 Cr |
| FY24 | ₹0 Cr | −₹0 Cr |
| FY23 | ₹0 Cr | −₹1 Cr |
| FY22 | ₹0 Cr | ₹2 Cr |
| FY21 | ₹0 Cr | −₹1 Cr |
| FY20 | ₹1 Cr | −₹2 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 25.44%
- Foreign institutions: 0.00%
- Domestic institutions: 0.00%
- Non-institutions: 74.56%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [KK Shah Hospita](https://app.pivotnow.in/stock/KKSHL) | — | ₹30 Cr | — | — |
| [Panjon](https://app.pivotnow.in/stock/PANJON) | — | ₹30 Cr | — | — |
| [Soni Medicare](https://app.pivotnow.in/stock/SML) | — | ₹30 Cr | — | — |
| [Chennai Meenaks](https://app.pivotnow.in/stock/CMMHOSP) | — | ₹29 Cr | — | — |
| [Tejnaksh](https://app.pivotnow.in/stock/TEJNAKSH) | — | ₹29 Cr | — | — |
| [Parmax Pharma](https://app.pivotnow.in/stock/PARMAX) | — | ₹25 Cr | — | — |

## Questions and answers

### What is the market cap of SAMSRITA LABS?

SAMSRITA LABS's market capitalisation is ₹28 Cr (₹28 Cr) at the 22 Oct 2026 close, ranking 3413th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of SAMSRITA LABS?

Return on equity was −69.4% in FY26 and return on capital employed was −73.3% in FY26 (consolidated figures).

### Is SAMSRITA LABS a debt-free company?

No. SAMSRITA LABS's debt-to-equity ratio was 0.14 in FY26, with total debt of ₹0 Cr.

### What were SAMSRITA LABS's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), SAMSRITA LABS reported revenue of ₹347 Cr, +8.7% year on year, and net profit of ₹22 Cr, +7.0% year on year.

### What is the shareholding pattern of SAMSRITA LABS?

As of 30 Jun 2026: promoters 25.44%, foreign institutions 0.00%, domestic institutions 0.00%, non-institutions 74.56%.

### Who are SAMSRITA LABS's competitors?

The listed Pharma & Healthcare companies closest to SAMSRITA LABS by market cap are KK Shah Hospita, Panjon, Soni Medicare, Chennai Meenaks, Tejnaksh and Parmax Pharma.

### Is SAMSRITA LABS a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out SAMSRITA LABS's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SAMSRITA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.